超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

瑞萊,ReLIA Diagnostics,  
瑞萊生物工程（深圳）有限公司是美國加州著名的 ReLIA 生物科技公司在中國的獨資企業，于2001年在深圳市高新技術產業園區注冊成立，注冊資金440萬美元，投資總額800多萬美元。

公司主要從事高新生物技術產品的研發及產業化生產,其自主開發的ReLIA檢驗系統與21世紀世界醫學檢驗學的重要發展趨勢同步，具備“快速、簡便、全血、定量檢測”等床邊即時檢驗技術（POCT）的各種優點，是國內率先擁有多項國際自主知識產權的POCT技術體系。企業已獲得國家食品藥品監督管理局(SFDA)頒發的《藥品生產許可證》和《醫療器械生產許可證》等證書，相關診斷試劑產品和檢驗儀器均擁有產品注冊證書。

公司擁有國際一流的研發和生產基地,其10萬級GMP標準潔凈廠房已獲得國家藥監局(SFDA)的GMP認證,生產和質量管理體系完全按照藥品GMP、ISO13485以及歐盟CE-MARK標準執行。

Rutter 博士現為 ReLIA（瑞萊）生物科技公司的董事長、美國高科技控股公司 Synergenics 的董事長兼首席執行官，美國科學院院士、加州大學醫學院 (UCSF) 榮譽教授。 Rutter 博士曾創辦美國著名的生物制藥企業 Chiron 公司，并任該公司董事長多年，同時還兼任國際大型制藥企業如諾華 Novartis 公司、默克 Merck 公司的董事會成員。

Rutter 博士在國際生物技術和重組基因工程領域做出過許多重大的貢獻。他領導的實驗室首次克隆了人類胰島素基因、首次利用 DNA 重組技術研制出乙型肝炎疫苗，1987 年更是首先發現并克隆了丙型肝炎病毒HCV，為發展高靈敏度病毒檢測試劑、疫苗以及治療藥物奠定了良好的基礎，先后發表了 380 多篇學術論文。他曾任美國加州大學醫學院生物化學系主任多年，任內該系誕生過兩位諾貝爾醫學獎獲得者。

Our goal is to provide central lab quality diagnostic testing to medical caregivers wherever fast, on-the-spot blood tests can improve the quality of patient care. When multiple biomarkers together can provide better information than a single biomarker can, we provide low-cost multiplexed tests with instant decision-making information. Bringing timely, high quality diagnostic information to the point-of-care will enhance the patient-doctor discussion and personalize follow-up treatment. Our strategy is to offer cardiovascular, cerebrovascular, acute kidney injury, and infectious disease biomarker panels in customer-proximity and point-of-care locations throughout the world.

Founder

William J. Rutter, Founder

Dr. Bill Rutter is Chairman and founder of ReLIA. The company is located in San Francisco’s Mission Bay /UCSF biomedical complex. It is a privately held company, under the umbrella of Synergenics LLC.

Dr. Rutter is also Chairman and CEO of Synergenics, which provides an innovative approach to advancing medical innovation into profitable start-up companies in the life sciences industry. Synergenics provides member companies (e.g., Humabs, Ventria, Synco, Numera, Pathologica, BioE, Epitomics) with investment, shared laboratories, scientific and industry expertise, and experienced management and administrative services. Synergenics provides a collaborative environment for the exchange of ideas and technology, while protecting each company’s IP.

Dr. Rutter is a member of the National Academy of Sciences and American Academy of Arts and Sciences and he has received numerous awards for his contributions to science and the biotechnology industry. He is Herzstein Professor Emeritus of Biochemistry at the University of California, San Francisco (UCSF). He co-founded Chiron Corporation (NASD: CHIR, acquired in 2005 by Novartis) and served as its Executive Chairman. Since the acquisition, Novartis has continued to build upon Chiron’s leadership in molecular diagnostic and vaccines. He has served on the boards of Novartis and numerous public and private biotechnology companies.